Skip to main content

Market Overview

What The Copaxone Court Ruling Means For Teva Pharmaceuticals

What The Copaxone Court Ruling Means For Teva Pharmaceuticals

“The district court ruled against Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) in the Copaxone 40mg patent case, invalidating each of the four patents in the case,” Deutsche Bank’s Gregg Gilbert said in a note, while maintaining a Buy rating on the company, with a price target of $48.

Negative Ruling

Although there are two more patents being litigated separately, and Teva Pharma is planning an immediate appeal, the analyst believes the decision “opens the door to potential at-risk generic launches” in 2017.

Gilbert pointed out that since there had been investor concerns regarding management credibility and three of the company’s patents not faring well in the inter parties review (IPR) process, investors had been expecting a negative ruling, with generic competition kicking off either in 2017 or 2018.


“To factor in the potential risk of generic competition to Copaxone 40mg, we model generic erosion starting in 2H17, with ~40 percent sales erosion in 2018 (first full year), followed by 15 percent annual erosion,” the analyst stated.

While these estimates could prove conservative, since Teva Pharma has been able to successfully manage the generic erosion of Copaxone 20mg.

At last check, shares of Teva were down 4.08 percent at $33.11.

Image Credit: By Mariusz Ch. - Own work, CC BY-SA 3.0, via Wikimedia Commons

Latest Ratings for TEVA

May 2021UBSDowngradesBuyNeutral
Nov 2020OppenheimerInitiates Coverage OnPerform
Nov 2020BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration Legal Analyst Ratings Best of Benzinga

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at